{
    "nctId": "NCT02738970",
    "briefTitle": "A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)",
    "officialTitle": "A Phase I, Open-Label, Two-Part, Multicenter Perjeta\u00ae Subcutaneous Dose-Finding Study in Combination With Herceptin\u00ae in Healthy Male Volunteers and Female Patients With Early Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Early Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 88,
    "primaryOutcomeMeasure": "Area Under the Concentration from Time Zero to Time Infinity (AUC0-inf) of Pertuzumab SC",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Part 1: Healthy male volunteers 18 to 45 years of age\n* Part 1: Left ventricular ejection fraction (LVEF) at least 55 percent (%)\n* Part 1: Body mass index (BMI) 18 to 32 kilograms per meter-squared (kg/m\\^2)\n* Part 1: Normal, intact skin without tattoos or lesions in the injection area\n* Part 2: Females at least 18 years of age\n* Part 2: Eastern Cooperative Oncology Group (ECOG) performance status of 0\n* Part 2: Previously treated, non-metastatic carcinoma of the breast\n* Part 2: Baseline LVEF at least 55%\n* Part 2: Negative pregnancy test and use of adequate contraceptive measures among women of childbearing potential\n\nExclusion Criteria:\n\n* Part 1: Positive urine test for drugs of abuse\n* Part 1: History of exposure or active viral infection of Hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)\n* Part 1: Cardiac disease including hypertension or hypotension\n* Part 1: Lower extremity edema\n* Part 1: Any clinically relevant history of systemic disease\n* Part 1: History of breast cancer\n* Part 1: Chronic corticosteroid use\n* Part 1: Receipt of IV antibiotics within 7 days prior to enrollment\n* Part 2: Concurrent malignancy requiring therapy that may interfere with pharmacokinetic investigations, or history of other malignancy within 5 years prior to Screening\n* Part 2: Significant cumulative exposure to anthracyclines\n* Part 2: Serious cardiac disease including uncontrolled hypertension\n* Part 2: Poor hematologic, renal, or hepatic function\n* Part 2: Pregnant or lactating women\n* Part 2: History of exposure or active viral infection of Hepatitis B, hepatitis C, or HIV\n* Part 2: Chronic corticosteroid use\n* Part 2: Receipt of IV antibiotics within 7 days prior to enrollment",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}